Jefferies reiterates Hana at buy

Hana Biosciences Inc. was reiterated by Jefferies & Co., Inc. analyst Adam Walsh at buy with a $16 price target. The company is well positioned for upside with Zensana under review by the Food and Drug Administration, three drug candidates in clinical trials, and significant news flow expected over the next 12 months. Shares of the South San Francisco, Calif.-based biopharmaceutical company were up 11 cents, or 1.38%, at $8.10, on volume of 260,592 shares versus the three-month running average of 208,194 shares. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.